Gregory,

76-year-old White mana

Based on his past treatment experience, Gregory is worried about serious side effects. Consider how you would balance slowing the disease with managing side effects in treatment discussions with your care team

Background

  • A sociable and active gardening enthusiast who enjoys walks with friends

MM diagnosis

  • Began experiencing constant fatigue and breathlessness. Lab tests showed he had MM

Current health, MM status, and concerns

  • High blood pressure
  • Relapsed MM with
  1. Treatment-related nerve pain and nausea
  2. Mild kidney disease
  3. Persistent fatigue and pain

Gregory's Treatment History

  • 54 MOFirst treatment: 3-drug combination regimen (PI, IMiD, and a steroid), followed by a stem cell transplant and an IMiD for maintenance therapy. Before transplant, he experienced severe nerve pain due to the PI
  • 14 MO First relapse: The hematologists tried a mAb-based 3-drug combination regimen (anti-CD38 mAb, IMiD, and a steroid), during which Gregory experienced mild pneumonia
  • 6 MO Second relapse: The doctor choose a 2-drug combination regimen (PI and a steroid), but Gregory experienced severe nerve pain and worsening high blood pressure
  • 18 MO Third relapse: The hematologist recommended a
    BCMA-directed CAR T-cell therapy. Gregory agreed and looked forward to the possibility of a treatment-free period; the treatment was well tolerated
  • Now: Fourth relapse
Treatment Goals and Considerations
  • His doctor notes his key treatment goal is achieving the best disease control
  • Gregory prefers a treatment that
  • ‒Prevents the myeloma from getting worse
  • ‒Has a lower risk of severe side effects he has struggled with previously

aThis patient profile is hypothetical and represents a type of patient typically seen in clinical practice.

BCMA, B-cell maturation agent; CAR, chimeric antigen receptor; CD, cluster of differentiation; IMiD, immunomodulatory drug; mAb, monoclonal antibody; MO, months; MM, multiple myeloma; PI, proteasome inhibitor.